nach oben

Journal of Neuro-Oncology

Erschienen in:

29.05.2017 | Clinical Study

Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab

verfasst von: Timo A. Auer, Mirjam Renovanz, Federico Marini, Marc A. Brockmann, Yasemin Tanyildizi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Bevacizumab (BVZ), a monoclonal antibody directed against vascular endothelial growth factor (VEGF), has been suspected to increase the incidence of ischemic stroke (IS) and intracranial hemorrhage (ICH) in GBM patients. Intracranial vascular events, such as IS and ICH, were retrospectively analyzed in 364 MRI scans of 82 patients with recurrent GBM (1st/2nd/3rd relapse). Out of these 82 patients, 40 were treated with BVZ (178 scans) in addition to basic treatment, whereas 42 patients matching for age and gender received basic treatment (186 scans). Distribution of typical vascular risk factors between both groups was analyzed retrospectively. In seven out of 82 patients (8%) vascular events were detected in MRI. Four vascular events were recorded in the BVZ-group (3 IS and 1 ICH), and 3 vascular events were found in the Control-group (1 IS and 2 ICH; p > 0.05 between both groups). Likewise, vascular risk factors (arterial hypertension, diabetes mellitus, obesity, former vascular event, hyperlipidemia, tobacco consumption and/or hypercholesterolemia) did not differ significantly between both groups. BVZ treatment does not seem to be associated with an increased risk for vascular events in patients with GBM in recurrence.

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507CrossRefPubMed

Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-oncology 17(Suppl 4):iv1–iv62CrossRefPubMedPubMedCentral

Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25(26):4127–4136CrossRefPubMed

Duda DG, Jain RK, Willett CG (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25(26):4033–4042CrossRefPubMedPubMedCentral

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21(21):2683–2710CrossRefPubMed

Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622CrossRefPubMed

Norden AD, Drappatz J, Wen PY (2009) Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5(11):610–620CrossRefPubMed

10.

Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D et al (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-oncology 13(10):1143–1150CrossRefPubMedPubMedCentral

11.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740CrossRefPubMed

12.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953CrossRefPubMed

13.

Heiland DH, Masalha W, Franco P, Machein MR, Weyerbrock A (2016) Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. J Neurooncol 126(3):567–575CrossRefPubMed

14.

Stupp R, Weller M (2014) Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro-oncology 16(6):765–767CrossRefPubMedPubMedCentral

15.

Kreisl TN, Toothaker T, Karimi S, DeAngelis LM (2008) Ischemic stroke in patients with primary brain tumors. Neurology 70(24):2314–2320CrossRefPubMed

16.

Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232–1239CrossRefPubMed

17.

Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27(29):4865–4873CrossRefPubMed

18.

Kuenen BC (2003) Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb 33(Suppl 1):13–14CrossRefPubMed

19.

Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D et al (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61(18):6624–6628PubMed

20.

Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neuro-oncology 99(1):49–56CrossRef

21.

Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM (2011) Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 105(2):281–289CrossRefPubMedPubMedCentral

22.

de Kock I, Mirhosseini M, Lau F, Thai V, Downing M, Quan H et al (2013) Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. J Palliat Care 29(3):163–169PubMed

23.

Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M et al (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32(6):1318–1322CrossRefPubMed

24.

Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin Cancer Res 12(16):4899–4907CrossRefPubMed

25.

Cemil B, Tun K, Polat O, Ozen O, Kaptanoglu E (2009) Glioblastoma multiforme mimicking arteriovenous malformation. Turk Neurosurg 19(4):433–436PubMed

26.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708CrossRefPubMedPubMedCentral

27.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722CrossRefPubMed

28.

Carden CP, Larkin JM, Rosenthal MA (2008) What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro-oncology 10(4):624–630CrossRefPubMedPubMedCentral

29.

Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Int Soc Cell 79(1–2):27–38

30.

Grisold W, Oberndorfer S, Struhal W (2009) Stroke and cancer: a review. Acta Neurol Scand 119(1):1–16CrossRefPubMed

31.

Whitaker RM (1998) Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 279(16):1265–1272CrossRef

32.

Dorresteijn LD, Kappelle AC, Boogerd W, Klokman WJ, Balm AJ, Keus RB et al (2002) Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 20(1):282–288CrossRefPubMed

33.

Wakai S, Yamakawa K, Manaka S, Takakura K (1982) Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 10(4):437–444CrossRefPubMed

34.

Zimmerman RA, Bilaniuk LT (1980) Computed tomography of acute intratumoral hemorrhage. Radiology 135(2):355–359CrossRefPubMed

35.

Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62CrossRefPubMed

36.

Eom KS, Kim DW, Kang S (2015) Emergency microsurgical embolectomy in acute ischemic stroke with diffusion-negative MRI. Neurol Neurochir Pol 49(6):432–435PubMed

37.

Bernick C, Kuller L, Dulberg C, Longstreth WT Jr, Manolio T, Beauchamp N et al (2001) Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57(7):1222–1229CrossRefPubMed

38.

Lim JS, Kwon HM (2010) Risk of “silent stroke” in patients older than 60 years: risk assessment and clinical perspectives. Clin Interv Aging 5:239–251PubMedPubMedCentral

39.

Vermeer SE, Longstreth WT Jr, Koudstaal PJ (2007) Silent brain infarcts: a systematic review. Lancet Neurol 6(7):611–619CrossRefPubMed

40.

Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL et al (2015) Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol 33(25):2735–2744CrossRefPubMedPubMedCentral

41.

Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T et al (2016) Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-oncology 18(9):1313–1318CrossRefPubMed

42.

Schaub C, Schafer N, Mack F, Stuplich M, Kebir S, Niessen M et al (2016) The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma. J Cancer Res Clin Oncol 142(8):1825–1829CrossRefPubMed

43.

Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Sangatsuda Y et al (2017) Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. OncoTargets Ther 10:429–437CrossRef

44.

Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T et al (2016) Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-oncology 18(7):991–1001CrossRefPubMedPubMedCentral

45.

Sinnadurai M, McDonald KL (2017) Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma. J Neuro-oncology 1–14

Titel: Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab
verfasst von: Timo A. Auer
Mirjam Renovanz
Federico Marini
Marc A. Brockmann
Yasemin Tanyildizi
Publikationsdatum: 29.05.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2467-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma

MGMT promoter methylation status: time for a frank discussion

Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas

Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review